- Home
- TBRG vs CMPX Comparison
TBRG vs CMPX Comparison
Compare TBRG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- CMPX
- Stock Information
- Founded
- TBRG 1979
- CMPX 2014
- Country
- TBRG United States
- CMPX United States
- Employees
- TBRG N/A
- CMPX N/A
- Industry
- TBRG
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- CMPX Health Care
- Exchange
- TBRG NYSE
- CMPX Nasdaq
- Market Cap
- TBRG 186.6M
- CMPX 217.4M
- IPO Year
- TBRG N/A
- CMPX N/A
- Fundamental
- Price
- TBRG $12.32
- CMPX $1.43
- Analyst Decision
- TBRG Buy
- CMPX Strong Buy
- Analyst Count
- TBRG 2
- CMPX 2
- Target Price
- TBRG $13.50
- CMPX $9.00
- AVG Volume (30 Days)
- TBRG 77.0K
- CMPX 429.9K
- Earning Date
- TBRG 11-06-2024
- CMPX 08-12-2024
- Dividend Yield
- TBRG N/A
- CMPX N/A
- EPS Growth
- TBRG N/A
- CMPX N/A
- EPS
- TBRG N/A
- CMPX N/A
- Revenue
- TBRG $336,557,000.00
- CMPX $850,000.00
- Revenue This Year
- TBRG $0.94
- CMPX N/A
- Revenue Next Year
- TBRG $4.58
- CMPX $950.68
- P/E Ratio
- TBRG N/A
- CMPX N/A
- Revenue Growth
- TBRG N/A
- CMPX N/A
- 52 Week Low
- TBRG $7.55
- CMPX $0.77
- 52 Week High
- TBRG $17.28
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- TBRG 55.21
- CMPX 60.03
- Support Level
- TBRG $11.72
- CMPX $1.19
- Resistance Level
- TBRG $12.84
- CMPX $1.61
- Average True Range (ATR)
- TBRG 0.43
- CMPX 0.10
- MACD
- TBRG -0.05
- CMPX 0.02
- Stochastic Oscillator
- TBRG 46.87
- CMPX 43.34
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.